Is there a Wegovy pill? What the MHRA approval means for you

What the MHRA approval confirmed, and what the trial evidence says

The regulator's green light in June 2026 was based on data from the OASIS 4 phase-3 trial: 307 adults with obesity or overweight plus at least one weight-related condition, no diabetes, followed for 64 weeks alongside lifestyle changes. Average body-weight reduction came in at roughly 13.6% against about 2.4% for placebo. Among participants who stuck fully to the regimen throughout, the figure rose to approximately 16.6%. Those two numbers are worth holding in mind separately, the first reflects real-world mixed adherence, the second shows the ceiling when the tablet is taken exactly as directed.

The active ingredient is semaglutide, the same molecule used in the weekly injection, co-formulated here with an absorption enhancer called SNAC that allows the medicine to cross the gut wall into the bloodstream. The GLP-1 receptor agonist mechanism is familiar: it slows the rate at which the stomach empties, reduces appetite signals in the brain, and helps the body regulate blood sugar. The tablet route does require stricter conditions to achieve that absorption, more on that below. You can read the MHRA's full announcement on GOV.UK's semaglutide approval news pages for the regulatory context.

Side effects reported in OASIS 4 followed the pattern seen with injectable semaglutide: gastrointestinal symptoms were the most common, affecting about 74% of tablet users compared with 42% in the placebo group. Most were mild to moderate and tended to ease as the body adjusted. Nausea, diarrhoea, vomiting and constipation were the most frequently cited. Dose escalation is gradual precisely to keep these manageable.

The four-step dose schedule and why the morning timing matters

The tablet schedule moves through four steps: 1.5 mg, then 4 mg, then 9 mg, reaching 25 mg as the maintenance dose, with at least a month at each level before moving up. That pace exists for tolerability; the gut needs time to adjust, and rushing the escalation is associated with more side effects rather than faster results.

Taking the tablet correctly is non-negotiable for absorption. It goes first thing in the morning, before anything else, on an empty stomach, with no more than about 120 ml of plain water (a small glassful). Then a wait of at least 30 minutes before coffee, breakfast, other oral medicines, or anything else. The SNAC enhancer can only do its job in that specific gastric environment; food or other drinks change the conditions and reduce how much semaglutide actually reaches the bloodstream. Think of it like the kettle rule: tablet first, then the kettle.

For anyone already established on the 2.4 mg weekly injection, the licensed guidance allows a move directly to the 25 mg tablet, though that switch still needs clinical assessment and prescriber sign-off rather than a self-directed swap. If you are weighing up the injection and tablet routes side by side, our page on what the Wegovy tablet involves covers the practical differences in more detail, and semaglutide tablets in the UK sets the full licensed picture.

Who the tablet is licensed for, and what it does not cover

The UK licence covers adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, obstructive sleep apnoea, or cardiovascular disease. Treatment is taken alongside a reduced-calorie diet and increased physical activity, the tablet supports those changes, it does not replace them.

A few things the licence does not cover. The Wegovy tablet is not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive. It is not licensed for under-18s. People with a history of medullary thyroid carcinoma, MEN2, or certain gastrointestinal conditions need a careful prescriber conversation before anything is started. BMI alone is never the deciding factor; the prescriber looks at the whole clinical picture.

One point worth flagging clearly: Rybelsus is also an oral semaglutide tablet, but it is licensed for type 2 diabetes management, not weight loss, and the dose steps are different (3 mg, 7 mg, 14 mg). The two products are not interchangeable. If you encounter a source describing those strengths in a weight-loss context, treat that as a red flag. If you are wondering whether there is a pill version of Wegovy and how it differs from Rybelsus, the NHS medicines page for semaglutide explains the distinction clearly.

For a broader look at how the Wegovy tablet compares with other licensed options, the weight-loss pills similar to Wegovy page covers the alternatives currently available in the UK. If cost is a practical question for you, the Wegovy pill cost page addresses what private treatment typically involves.

NHS availability, private access, and the practical next step

The tablet is not currently available on the NHS. A NICE technology appraisal would be needed before it could be commissioned, and that process takes time. Private prescription is the route at launch, which means a clinical consultation first, then a prescription if the prescriber decides the medicine is appropriate.

At nume, every consultation is read the same day by a GPhC-registered Independent Prescriber: a real clinician, not automated software. There are no subscriptions or auto-renewals; each repeat order gets its own clinical review. The tablet stores at room temperature, so there are no cold-chain complications with delivery, practical whether your order lands before a bank holiday, around a busy patch at work, or any other week when you'd rather not think about logistics. Once approved, orders placed before 12pm on a working day are dispatched the same day, arriving free via tracked DPD the next working day in plain, unbranded packaging.

You can verify our GPhC registration at GPhC premises register number 9012878. If you are still exploring whether there is a pill form of Wegovy that suits your circumstances, or want to find out whether the Wegovy tablet is suitable for you, or to explore the full range of licensed weight-loss treatments we offer, the best starting point is a free consultation with our prescribers.

Speak to our prescribers, start your free consultation here.